Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

'Irreversible' endothelin-1 binding does not prohibit ABT-627 from reversing endothelin-1-induced effects.

W J Chiou1, J L Wessale, T von Geldern

  • 1Pharmaceutical Products Division, Abbott Laboratories, Abbott Park, Illinois, USA.

Journal of Cardiovascular Pharmacology
|November 15, 2000
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Potential for vitamin D receptor agonists in the treatment of cardiovascular disease.

British journal of pharmacology·2009
Same author

Vitamin D receptor: a highly versatile nuclear receptor.

Kidney international·2007
Same author

Statins do not directly activate vitamin D receptor.

Journal of thrombosis and haemostasis : JTH·2006
Same author

Effect of ABT-627 (A-147627), a potent selective ET(A) receptor antagonist, on the cardiopulmonary profile of newborn lambs with surgically-induced diaphragmatic hernia.

British journal of pharmacology·2001
Same author

New antimitotic agents with activity in multi-drug-resistant cell lines and in vivo efficacy in murine tumor models.

Journal of medicinal chemistry·2001
Same author

Pyrrolidine-3-carboxylic acids as endothelin antagonists. 5. Highly selective, potent, and orally active ET(A) antagonists.

Journal of medicinal chemistry·2001

ABT-627, an endothelin-A receptor antagonist, effectively reverses endothelin-1-induced vasoconstriction. This compound shows promise for treating pathological conditions driven by endothelin-1 signaling.

Area of Science:

  • Pharmacology
  • Cardiovascular Research
  • Molecular Biology

Background:

  • Endothelin-1 (ET-1) is implicated in various diseases due to its potent, long-lasting vasoconstrictor effects.
  • ET-1's sustained action may involve irreversible receptor binding and internalized receptor signaling.
  • Understanding ET-1 receptor interactions is crucial for developing targeted therapies.

Purpose of the Study:

  • To characterize the binding and functional properties of ABT-627, a selective endothelin-A (ET(A)) receptor antagonist.
  • To evaluate the efficacy of ABT-627 in reversing ET-1-mediated vasoconstriction in vitro and in vivo.
  • To assess ABT-627's potential therapeutic value in ET-1-related pathologies.

Main Methods:

  • In vitro receptor binding assays using Chinese hamster ovary (CHO) cells expressing human ET(A) receptors.

Related Experiment Videos

  • Assessment of ET-1 and ABT-627 binding kinetics, including dissociation half-life.
  • Ex vivo studies using rat aortic rings to measure ET-1-induced contraction reversal by ABT-627.
  • In vivo experiments in anesthetized rats to evaluate ABT-627's effect on ET-1-induced changes in arterial pressure.

    • Main Results:

    • ABT-627 demonstrated potent and selective binding to human ET(A) receptors (Ki = 0.034 nM) with reversible kinetics (t1/2 = 2 h).
    • While both ET-1 and ABT-627 induced partial ET(A) receptor internalization, only ET-1 triggered intracellular responses.
    • ABT-627 dose-dependently reversed ET-1-induced contractions in rat aortic rings and normalized arterial pressure in vivo.

    Conclusions:

    • ABT-627 acts as a reversible ET(A) receptor antagonist with distinct binding characteristics compared to ET-1.
    • ABT-627 effectively reverses established ET-1-mediated vasoconstriction both in vitro and in vivo.
    • These findings highlight ABT-627's therapeutic potential for pathological conditions associated with excessive ET-1 activity.